US FDA accepts ChemGenex's Omapro NDA filing to treat CML, grants priority review status
Thursday, November 12, 2009 18:00 IST Melbourne, Australia
ChemGenex Pharmaceuticals Limited announced that the US Food & Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for Omapro (omacetaxine mepesuccinate) for the treatment